Paper · 29023213

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Horn L and 28 others. J Clin Oncol, 2017. Cited by 731 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). Papers, record 29023213. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29023213

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).; PubMed
Journal: J Clin Oncol; PubMed
Year: 2017; PubMed
Publication types: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/29023213/; PubMed
DOI: https://doi.org/10.1200/jco.2017.74.3062; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC6075826/; PubMed
The journal: https://conductscience.org/library/journal-index/8309333; PubMed
Citations, by iCite: 731; iCite
Relative citation ratio, by iCite: 22.2; iCite
Revised in PubMed: 2022-04-10; PubMed

Authors29

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Horn L	Leora
2	Spigel DR	David R
3	Vokes EE	Everett E
4	Holgado E	Esther
5	Ready N	Neal
6	Steins M	Martin
7	Poddubskaya E	Elena
8	Borghaei H	Hossein
9	Felip E	Enriqueta
10	Paz-Ares L	Luis

1 to 10 of 29Source PubMed

See all 29 authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antibodies, Monoclonal	Major topic
Antineoplastic Agents	Major topic
Carcinoma, Non-Small-Cell Lung	Major topic
Lung Neoplasms	Major topic
Taxoids	Major topic
Docetaxel
Humans
Kaplan-Meier Estimate
Nivolumab
Survival Rate
Treatment Outcome

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
P30 CA008748	NCI NIH HHS	United States	P30CA008748	PubMed and NIH

Source NIH RePORTER

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record	Source
NCT01642004	Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)	Derived from the trial	Yes	ClinicalTrials.gov
NCT01673867	Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC	Derived from the trial	Yes	ClinicalTrials.gov
NCT05715229	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy	Background		ClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Comment in	29,782,565	Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution.	https://conductscience.org/library/papers/29782565

Source PubMed

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	26,412,456	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.	N Engl J Med	2015	https://conductscience.org/library/papers/26412456	PubMed
2	26,884,577	Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.	J Clin Oncol	2016	https://conductscience.org/library/papers/26884577	PubMed
3	25,482,239	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.	N Engl J Med	2015	https://conductscience.org/library/papers/25482239	PubMed
4	26,406,148	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.	N Engl J Med	2015	https://conductscience.org/library/papers/26406148	PubMed
5	22,437,870	The blockade of immune checkpoints in cancer immunotherapy.	Nat Rev Cancer	2012	https://conductscience.org/library/papers/22437870	PubMed
6	27,401,894	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.	Oncologist	2016	https://conductscience.org/library/papers/27401894	PubMed
7	25,399,552	Nivolumab in previously untreated melanoma without BRAF mutation.	N Engl J Med	2015	https://conductscience.org/library/papers/25399552	PubMed
8	25,651,787	Global cancer statistics, 2012.	CA Cancer J Clin	2015	https://conductscience.org/library/papers/25651787	PubMed
9	26,712,084	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.	Lancet	2016	https://conductscience.org/library/papers/26712084	PubMed
10	19,097,774	New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).	Eur J Cancer	2009	https://conductscience.org/library/papers/19097774	PubMed

1 to 10 of 15

See all 15 references

Cited by533

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 731 citations.

PMID	Title	Journal	Year	In Papers	Source
42,882,056	Prognostic Value of Pretreatment Modified Glasgow Prognostic Score in Nivolumab-Treated Advanced Non-Small Cell Lung Cancer.	J Clin Med	2026	https://conductscience.org/library/papers/42882056	PubMed
42,403,504	CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancer.	Ther Adv Med Oncol	2026	https://conductscience.org/library/papers/42403504	PubMed
42,376,198	Contrast-enhanced CT based radiomics for prediction of 3-year disease progression in NSCLC patients after anti-PD-1-targeted therapy.	Eur J Radiol Open	2026	https://conductscience.org/library/papers/42376198	PubMed
42,246,395	Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model.	Health Technol Assess	2026	https://conductscience.org/library/papers/42246395	PubMed
42,169,779	Methyltransferase-Like 3 Inhibition-Activated cGAS/STING Axis Enhances Immunotherapy and Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity in Lung Adenocarcinoma.	Research (Wash D C)	2026	https://conductscience.org/library/papers/42169779	PubMed
42,103,792	Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients.	Sci Rep	2026	https://conductscience.org/library/papers/42103792	PubMed
41,938,478	A Novel Strategy for Treating Elderly Patients with Advanced Non-Small Cell Lung Cancer: Exploring the Efficacy and Safety of Anlotinib Combined with PD-1/PD-L1 Inhibitors.	Onco Targets Ther	2026	https://conductscience.org/library/papers/41938478	PubMed
41,868,678	Effectiveness and safety of recombinant human endostatin injection plus immune checkpoint inhibitors for non-small cell lung cancer: a single-centered, retrospective study.	Am J Cancer Res	2026	https://conductscience.org/library/papers/41868678	PubMed
41,862,951	Comprehensive clinicopathological and prognostic analysis of primary pulmonary lymphoepithelial carcinoma: a retrospective cohort study.	Diagn Pathol	2026	https://conductscience.org/library/papers/41862951	PubMed
41,811,469	A single-arm phase Ib study of personalized peptide-pulsed dendritic cell-based multiple target cytotoxic T lymphocyte immunotherapy in combination with toripalimab as second-line therapy in advanced non-small-cell lung cancer.	Cancer Immunol Immunother	2026	https://conductscience.org/library/papers/41811469	PubMed

1 to 10 of 533

See all 533 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
NIVOLUMAB	CHEMBL2108738	Derived from the trial	2	https://conductscience.org/library/drugs/CHEMBL2108738	ChEMBL
DOCETAXEL	CHEMBL3545252	Derived from the trial	2	https://conductscience.org/library/drugs/CHEMBL3545252	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29023213

GET https://conductscience.org/api/papers/v1/29023213/authors?page=2

API reference For AI assistants